Cellular Matrix - Model BCT-HA - Medical Device Class III
Cellular Matrix tubes allow the preparation of autologous platelet-rich plasma (RegenPRP) combined with a non-crosslinked hyaluronic acid (HA) in a closed-circuit system. CM-PRP-HA has an excellent safety profile in clinical practice.1,3,4 Cellular Matrix technology combines the complementary clinical effects of RegenPRP and hyaluronic acid (HA), giving better and longer-lasting results in patients with osteoarthritis.1,3,4
-
Most popular related searches
Hyaluronic Acid
Hyaluronic acid is a major component of synovial fluid contributing to joint homeostasis.
- 25 years of clinical experience shows pain relief and functional improvement lasting 6 to 12 months in OA patients.
- Plays a major role in viscosupplementation and pain relief in OA.5
- The network of HA chains generates an ideal cell-friendly matrix when combined with PRP.6
Hyaluronic acid improves the activity of several molecules contained in platelet-rich plasma to provide additional benefits to OA patients1.
Both PRP and HA have been extensively used to improve lubrication, modulate inflammation and modify the joint catabolic micro-environment, aiming not only to reduce clinical symptoms, but also to slow down OA progression2.
When PRP and HA are used in combination these effects are enhanced and prolonged. HA creates a bioactive scaffolding in which the platelets progressively release their growth factors. RegenPRP does not negatively affect the mechanical, elastic or viscous properties of HA1.
When PRP and HA are used in combination these effects are enhanced and prolonged. HA creates a bioactive scaffolding in which the platelets progressively release their growth factors. RegenPRP does not negatively affect the mechanical, elastic or viscous properties of HA1.
Technology Advantages
- User-independent standardized preparation
- Minimum volume of blood required
- Safe closed-circuit system
- Mechanical isolation of PRP using a biologically inert gel after a 5-minute centrifugation
- Reversible anticoagulation with a pharmaceutical grade solution of sodium citrate at pH 7
- Minimal learning curve and ease of use
- Operationally and clinically efficient process
- Facilitates and streamlines routine practice
- Certified technology for the preparation of RegenPRP® combined with hyaluronic acid (HA) (CM-PRP-HA)
- Contains 2 ml of non-crosslinked HA at a concentration of 20 mg/ml (40 mg total)
- HA produced by bacterial fermentation, thus free of animal proteins
- Demonstrated safety and efficacy
- Evidence-based outcomes for numerous therapeutic indications
- Large number of clinical studies, with over 200 publications
- RegenPRP is standardized, leucocyte reduced and easily reproducible
Regen Lab specific separating gel technology guarantees minimal variability - Platelets recovery in CM-PRP-HA >70%
- High platelet quality
Viable & functional platelets - Full plasma recovery
No loss of plasma growth factors and fibrinogen - Leucocyte reduced PRP Depletion ~ 94.3% of pro-inflammatory granulocytes, leaving mainly lymphocytes and monocytes
- Virtually no red blood cells
Depletion of ~ 99.5% of erythrocytes
RegenPRP Standardized Performance
BCT-HA Tube Properties
BLOOD SAMPLE VOL PER TUBE
4 ml
PRP VOL PER TUBE
~2 ml of PRP combined with 2 ml of HA
PLATELET RECOVERY
> 70 %
GRANULOCYTE DEPLETION
94.3 %
RED BLOOD CELL DEPLETION
99.5 %
Customer reviews
No reviews were found for Cellular Matrix - Model BCT-HA - Medical Device Class III. Be the first to review!